Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter, efficacy and safety study of quarfloxin in
patients with low or intermediate grade neuroendocrine cancer. The purpose of this study is
to evaluate the rate of clinical benefit response to quarfloxin treatment including the
reduction in secretory symptoms of flushing and/or diarrhea or the reduction quantifiable
hormones or other biochemical tumor markers.